Shelley J. Force Aldred, Ph.D.
Affiliations: | Stanford University, Palo Alto, CA |
Google:
"Shelley Force Aldred"Mean distance: 16440.9
Parents
Sign in to add mentorRichard Morris Myers | grad student | 2005 | Stanford | |
(Large scale identification and analysis of human transcriptional regulatory elements.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Trinklein ND, Pham D, Schellenberger U, et al. (2019) Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. Mabs |
Clarke S, Dang K, Li Y, et al. (2019) A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: 324-324 |
Buelow B, Clarke S, Dang K, et al. (2019) Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: e16519-e16519 |
Malik H, Buelow B, Rangaswamy U, et al. (2019) TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion Blood. 134: 4070-4070 |
Clarke SC, Ma B, Trinklein ND, et al. (2018) Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies. Frontiers in Immunology. 9: 3037 |
Buelow B, Choudhry P, Clarke S, et al. (2018) Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 60-60 |
Force Aldred S, Boudreau A, Buelow B, et al. (2018) Multispecific antibodies targeting CD38 show potent tumor-specific cytotoxicity. Journal of Clinical Oncology. 36: 57-57 |
Rangaswamy U, Boudreau A, Buelow B, et al. (2018) A novel T-cell bispecific antibody platform for efficient T-cell mediated killing of tumor cells with minimal cytokine release. Journal of Clinical Oncology. 36: 209-209 |
Buelow B, Choudry P, Clarke S, et al. (2018) Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 8034-8034 |
Malik H, Buelow B, Avanzino B, et al. (2018) A Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills Lymphoma Cells with Minimal Cytokine Secretion Blood. 132: 1671-1671 |